NO991186D0 - Bruk av leptinantagonister for behandling av insulinresistens ved type-II-diabetes - Google Patents

Bruk av leptinantagonister for behandling av insulinresistens ved type-II-diabetes

Info

Publication number
NO991186D0
NO991186D0 NO991186A NO991186A NO991186D0 NO 991186 D0 NO991186 D0 NO 991186D0 NO 991186 A NO991186 A NO 991186A NO 991186 A NO991186 A NO 991186A NO 991186 D0 NO991186 D0 NO 991186D0
Authority
NO
Norway
Prior art keywords
diabetes
treatment
type
insulin resistance
leptin antagonists
Prior art date
Application number
NO991186A
Other languages
English (en)
Norwegian (no)
Other versions
NO991186L (no
Inventor
Johann Ertl
Gerald Preibisch
Guenter Mueller
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO991186L publication Critical patent/NO991186L/no
Publication of NO991186D0 publication Critical patent/NO991186D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO991186A 1996-09-20 1999-03-11 Bruk av leptinantagonister for behandling av insulinresistens ved type-II-diabetes NO991186D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19638487 1996-09-20
PCT/EP1997/005035 WO1998012224A1 (en) 1996-09-20 1997-09-15 Use of leptin antagonists for treating insulin resistance in type ii diabetes

Publications (2)

Publication Number Publication Date
NO991186L NO991186L (no) 1999-03-11
NO991186D0 true NO991186D0 (no) 1999-03-11

Family

ID=7806282

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991186A NO991186D0 (no) 1996-09-20 1999-03-11 Bruk av leptinantagonister for behandling av insulinresistens ved type-II-diabetes

Country Status (18)

Country Link
US (1) US6399745B1 (es)
EP (1) EP0956302A1 (es)
JP (1) JP2001500869A (es)
KR (1) KR20010029537A (es)
CN (1) CN1230966A (es)
AR (1) AR008444A1 (es)
AU (1) AU735178B2 (es)
BR (1) BR9711513A (es)
CA (1) CA2266585A1 (es)
CZ (1) CZ90999A3 (es)
HU (1) HUP9904023A3 (es)
ID (1) ID21861A (es)
IL (1) IL129057A0 (es)
NO (1) NO991186D0 (es)
PL (1) PL332458A1 (es)
RU (1) RU2201249C2 (es)
WO (1) WO1998012224A1 (es)
ZA (1) ZA978455B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1101112B1 (en) 1998-07-28 2004-10-06 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Leptin-mediated gene-induction
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
WO2001021647A2 (en) * 1999-09-22 2001-03-29 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
AU8178401A (en) 2000-05-22 2001-12-03 Vlaams Interuniv Inst Biotech Receptor-based interaction trap
US7235629B2 (en) 2000-11-14 2007-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional fragment of the leptin receptor
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CN102174115B (zh) 2004-02-11 2014-05-14 安米林药品有限责任公司 具有可选择特性的杂合多肽
US7407929B2 (en) * 2004-05-07 2008-08-05 Boston Biomedical Research Institute Leptin peptide antagonists
US7423113B2 (en) 2004-08-25 2008-09-09 Vib Vzw Leptin antagonist
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2127676A3 (en) * 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
CA2585549A1 (en) 2004-11-18 2006-05-26 Vib Vzw Novel type leptin receptor antagonist
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
NZ561361A (en) 2005-02-11 2010-02-26 Amylin Pharmaceuticals Inc GIP hybrid polypeptides with at least two hormonal activities
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US20100004166A1 (en) * 2006-03-23 2010-01-07 Richard Pittner Endothelin and Endothelin Receptor Agonists in the Treatment of Metabolic Diseases
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
AU2007360979B2 (en) * 2007-11-14 2014-04-10 Amylin Pharmaceuticals, Llc Methods for treating obesity and obesity related diseases and disorders
WO2010117785A1 (en) * 2009-03-31 2010-10-14 Temple University - Of The Commonwealth System Of Higher Education Leptin antagonist and methods of use
US20120071401A1 (en) 2009-04-10 2012-03-22 Amylin Pharamaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
ES2873253T3 (es) 2010-09-28 2021-11-03 Amryt Pharmaceuticals Inc Leptinas altamente solubles
WO2013009539A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
PT2900230T (pt) 2012-09-27 2018-11-26 Massachusetts Gen Hospital Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
AU2014354831B2 (en) 2013-11-26 2017-10-26 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN104829707B (zh) 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
CN104829708B (zh) 2015-05-06 2017-11-28 广东省生物资源应用研究所 一条d螺旋区突变的瘦素活性肽及其编码基因和应用
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
JP7139317B2 (ja) 2016-09-12 2022-09-20 アムリット・ファーマシューティカルズ・インコーポレイテッド 抗レプチン中和抗体を検出する方法
EP3675961A1 (en) * 2017-08-31 2020-07-08 University Of Dundee Leptin peptides and their use for treating neurological disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5574133A (en) * 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) * 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5525705A (en) * 1995-01-31 1996-06-11 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
KR19990028388A (ko) * 1995-06-30 1999-04-15 피터 지. 스트링거 당뇨병 치료 방법
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US5922678A (en) * 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes

Also Published As

Publication number Publication date
NO991186L (no) 1999-03-11
US6399745B1 (en) 2002-06-04
WO1998012224A1 (en) 1998-03-26
JP2001500869A (ja) 2001-01-23
AU4458697A (en) 1998-04-14
KR20010029537A (ko) 2001-04-06
ZA978455B (en) 1998-03-20
HUP9904023A2 (hu) 2000-03-28
PL332458A1 (en) 1999-09-13
CA2266585A1 (en) 1998-03-26
CN1230966A (zh) 1999-10-06
RU2201249C2 (ru) 2003-03-27
IL129057A0 (en) 2000-02-17
BR9711513A (pt) 1999-08-24
EP0956302A1 (en) 1999-11-17
CZ90999A3 (cs) 1999-06-16
ID21861A (id) 1999-08-05
AU735178B2 (en) 2001-07-05
HUP9904023A3 (en) 2002-01-28
AR008444A1 (es) 2000-01-19

Similar Documents

Publication Publication Date Title
NO991186L (no) Bruk av leptinantagonister for behandling av insulinresistens ved type-II-diabetes
DE122004000049I1 (de) Neue Insulinderivate mit schnellem Wirkungseintritt.
DK0758255T3 (da) Sprøjte med lav modstand
DK0925083T3 (da) Engangssprøjte
FI955051A0 (fi) Heterosyklisiä yhdisteitä ja niiden valmistus ja käyttö
BR9612678A (pt) Seringa descartável
ATE298337T1 (de) Neue verwendung sowie neue n-azabicycloamid- verbindungen
HK1045111B (zh) 用於治療胰島素的抗阻和二型糖尿病之(3-三鹵代甲基苯氧基) (4-鹵代苯基) ((3-trihalo-methylphenoxy)(4-halophenyl))
CY2007001I1 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
EE9700363A (et) Uus anesteseeriva toimega farmatseutiline segu
EG21712A (en) Treatment of insulin resistance
PT1017408E (pt) Utilizacao de tetra-hidrolipstatina no tratamento de diabetes de tipo ii
IL133136A0 (en) Use of leptin antagonists for the treatment of diabetes
NO990097D0 (no) Ny behandling av leptin-resistens
NO975718D0 (no) Behandling av insulinresistens
DE69717535T2 (de) Katheterspritzenrichter
FI971317A (fi) Uusia heterosyklisiä, substituoituja imidatsolokinoksalinoneja, niiden valmistus ja käyttö
EE200000712A (et) Eeltäidetud süstal ja selle kasutamine
FR2749172B1 (fr) Seringue hypodermique
NO995940D0 (no) Anvendelse av leptin antagonister for behandling av diabetes
ES1039049Y (es) Jeringuilla desechable perfeccionada.
EP1009232A4 (en) METHODS OF TREATING INSULIN RESISTANCE AND METHODS OF IDENTIFYING PATIENTS AT RISK
BR7401733U (pt) Seringa travável descartável
BR9601744A (pt) Seringa descartável aperfeiçoada
IT243703Y1 (it) Siringa perfezionata

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application